Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | ATP4A | P20648 | 7/20 | 0.44 |
| ▸ | ATP4B | P51164 | 7/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4984430 | 0.73 | HSD17B10 (0.47) | RAB9ANPC1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL2211852 | 0.73 | ALDH1A1 (0.46) | RAB9ANPC1HTTALDH1A1LMNA | |
| SCHEMBL2211854 | 0.73 | ALDH1A1 (0.46) | RAB9ANPC1HTTALDH1A1LMNA | |
| SCHEMBL6985595 | 0.72 | MAPT (0.57) | RAB9ANPC1ATP4AATP4B | |
| Hydrochloric Acid SCHEMBL6989280 | 0.71 | MAPT (0.56) | RAB9ANPC1ATP4AATP4B | |
| SCHEMBL24023331 | 0.70 | ALDH1A1 (0.36) | RAB9ANPC1ATP4AATP4BHTT | |
| SCHEMBL3086729 | 0.70 | ALDH1A1 (0.36) | RAB9ANPC1ATP4AATP4BHTT | |
| SCHEMBL14302479 | 0.70 | SMN1; SMN2 (0.36) | RAB9ANPC1ATP4AATP4BHTT | |
| SCHEMBL2304799 | 0.68 | SMN1; SMN2 (0.44) | RAB9ANPC1HTTALDH1A1LMNA | |
| SCHEMBL15275530 | 0.66 | ESR2 (0.75) | GAAKMT2ACYP2C9ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210353607-A1 | PI3K INHIBITORS AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2021-11-18 | — | — | US | disclosed |
| EP-2357179-A1 | Thiazol-2-yl organic compounds | Novartis AG (CH) | 2011-08-17 | — | — | EP | disclosed |
| US-7799810-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-21 | — | — | US | disclosed |
| US-7799810-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-21 | — | — | US | disclosed |
| US-7799810-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-21 | — | — | US | disclosed |
| US-7754746-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-07-13 | — | — | US | disclosed |
| US-7754746-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-07-13 | — | — | US | disclosed |
| US-7754746-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-07-13 | — | — | US | disclosed |
| US-20100120865-A1 | Organic compounds | NOVARTIS AG (CH) | 2010-05-13 | — | — | US | disclosed |
| US-20100120865-A1 | Organic compounds | NOVARTIS AG (CH) | 2010-05-13 | — | — | US | disclosed |
| EP-2035413-A2 | THIAZOLYL UREA DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | Novartis AG (CH) | 2009-03-18 | — | — | EP | disclosed |
| CN-101374823-A | Organic compounds | NOVARTIS AG (CH) | 2009-02-25 | — | — | CN | disclosed |
| US-20080319033-A1 | 3-{3-[5-(4-acetylphenyl)-4-methylthiazol-2-yl]-ureido}-N-tert-butylpropionamide, exhibiting phosphatidylinositol 3-kinase inhibitory activity and used for treating respiratory system disorders, such as asthma | NOVARTIS AG | 2008-12-25 | — | — | US | disclosed |
| US-20080319033-A1 | 3-{3-[5-(4-acetylphenyl)-4-methylthiazol-2-yl]-ureido}-N-tert-butylpropionamide, exhibiting phosphatidylinositol 3-kinase inhibitory activity and used for treating respiratory system disorders, such as asthma | NOVARTIS AG | 2008-12-25 | — | — | US | disclosed |
| US-20080319033-A1 | 3-{3-[5-(4-acetylphenyl)-4-methylthiazol-2-yl]-ureido}-N-tert-butylpropionamide, exhibiting phosphatidylinositol 3-kinase inhibitory activity and used for treating respiratory system disorders, such as asthma | NOVARTIS AG | 2008-12-25 | — | — | US | disclosed |
| EP-1966175-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| WO-2008000421-A2 | THIAZOLYL UREA DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-01-03 | — | — | WO | disclosed |
| WO-2008000421-A2 | THIAZOLYL UREA DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-01-03 | — | — | WO | disclosed |
| WO-2007068473-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007068473-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120865-A1 | Organic compounds | PIK3C3, PIK3R3, PIK3R4 | RAB9A 337/4885NPC1 622/4885ATP4A 3170/4885 |
| US-20080319033-A1 | 3-{3-[5-(4-acetylphenyl)-4-methylthiazol-2-yl]-ureido}-N-tert-butylpropionamide, exhibiting phosphatidylinositol 3-kinase inhibitory activity and used for treating respiratory system disorders, such as asthma | AKT3, PIK3R3, PIK3CD | RAB9A 1515/4885NPC1 3385/4885ATP4A 1688/4885 |
| US-20210353607-A1 | PI3K INHIBITORS AND USES THEREOF | PIK3CA, AKT3, GSK3B | RAB9A 733/4885NPC1 721/4885ATP4A 1389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.